Fred Hutchinson Cancer Research Center (FHCRC) has been awarded a $4.3 million grant to continue research on the impact of genetics in stem cell transplant outcomes and complications for patients being treated for blood cancers.
The study, which expands on research begun in 2006, will attempt to identify genetic characteristics that put patients at increased risk for allogeneic transplant complications such as acute and chronic graft-vs-host-disease (GVHD), organ toxicities, infection, as well as relapse and overall survival.
With their results, researchers hope to improve risk assessment, education, and treatment planning. In addition, their findings may also help gain some further insight into the diseases themselves as well as provide the foundation for further study and development of therapies to control transplant complications.
It is estimated that by the end of 2011, more than 1 million people will have been treated with a stem cell transplant worldwide.